Chinook Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Chinook Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,914 of 15,742 sponsors by registered trial count).
Chinook Therapeutics: 4 sponsored US clinical trials, none currently recruiting.
Chinook Therapeutics sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is IgA Nephropathy, with 1 trials.
Upper-quartile sponsor footprint
Chinook Therapeutics sits in the upper quartile of the sponsor corpus (#2,914 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Atrasentan in Patients With IgA Nephropathy
NCT04573478
Open-label Safety and PK Study of BION-1301 in Japanese Healthy Subjects
NCT05508204
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CHK-336 in Healthy Volunteers
NCT05367661
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
NCT03340883
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 3 | 1 |
Therapeutic Areas
How the Chinook Therapeutics early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 1 completed (25%).
Phase mix: 1 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: IgA Nephropathy (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Chinook Therapeutics: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Chinook Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Chinook Therapeutics page
4 registered trials is a research-attention snapshot, not an endorsement of Chinook Therapeutics or any single study.
- None of Chinook Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- IgA Nephropathy is the condition Chinook Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See IgA Nephropathy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Chinook Therapeutics pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.